Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Prior treatment

• Any contraindications to study procedures or medications as outlined in the study protocol.
• Any prohibited medication as defined in the study protocol.
• Any significant concomitant disease that may require chronic treatment with systemic corticosteroids and/or systemic immunosuppressants during the study.

Other illness

• Current or history of any significant medical conditions as described in the study protocol.

Lab values

• Any abnormal laboratory blood values as defined in the study protocol.

Age

• Multiple sclerosis disease duration of ≥ 10 years in Participants with Expanded Disability Status Scale (EDSS) score of ≤ 2.5 at screening.

Other

• Diagnosis of primary progressive or with secondary progressive MS (Thompson et al, 2018).

• Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson et al, 2018).
• Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive.
• Evidence of recent MS activity as defined by the study protocol.
• Neurologically stable subject, with no relapse for ≤ 28 days before randomization.